Contraceptive BehaviorDepoTextNCT01641380
Meaningful Use of Technology to Improve Health Care Delivery
A study testing Text Messaging Intervention in people with Contraceptive Behavior, run by Johns Hopkins University at 1 site in United States.
Trial summary
While there have been major declines in teenage pregnancy around the country, Baltimore, Maryland has continued to experience increases over the last several years. Access and adherence to contraception has been found to be a major contributor to declines in teen pregnancy worldwide. Read more about this study
- Who is it for?
- Ages 13 to 21 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Contraceptive Behavior
- What is being tested?
- Text Messaging Intervention
- Type of treatment
- Injection or infusion, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 100 participants
- Where
- 1 siteUnited States
- Study dates
- Jan 2011to 1 Sep 2017
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 13 to 21 years
- Women only
- Healthy volunteers accepted
- Child, Adult
Who may be able to join
- Selected Depo-Provera for ongoing contraception
- Have a cell phone with text messaging capacity for personal use, and
- Agree to be randomized
Who cannot join
- Adolescent girls using other forms of contraception
- Adolescents who do not have a cell phone w/ text messaging capability for personal use
Trial locations and contacts
1 site in 1 country.
United States1 site
Johns Hopkins Children's Center
Baltimore, Maryland, 21287
About this study
Official title: Meaningful Use of Technology to Improve Health Care Delivery for Urban Adolescents: Focus on Teen Pregnancy Prevention (DepoText Study)
While there have been major declines in teenage pregnancy around the country, Baltimore, Maryland has continued to experience increases over the last several years. Access and adherence to contraception has been found to be a major contributor to declines in teen pregnancy worldwide. The aim of this proof of concept pilot project is to determine preliminary efficacy of the DepoText Intervention. We will randomize urban adolescent girls who have elected Depo-Provera for ongoing contraception to receive either standard counseling and clinic appointment reminders or a text messaging (DepoTEXT) follow-up intervention. Participants in the DepoTEXT intervention will receive reminders for clinic visits and encouraging messages each month for STI prevention. The primary outcome is the preliminary efficacy for improving appointment adherence.
Read the detailed description
Aims:
The aim of this proof of concept pilot project is to determine the feasibility and acceptability of a text messaging reminder system for communicating with urban adolescents using Depo-Provera for long-acting contraception. We will randomize urban adolescent girls who have elected Depo-Provera for ongoing contraception to receive either standard counseling and clinic appointment reminders or a text messaging (DepoTEXT) follow-up intervention. Participants in the DepoTEXT intervention will receive reminders for clinic visits and encouraging messages each month for STI prevention. The primary outcome is the preliminary efficacy for improving appointment adherence. Secondary measures include patient responsiveness to text messages and acceptability/satisfaction with this approach.
Setting and Participants:
This research study will be conducted in the Johns Hopkins Harriet Lane Clinic located Baltimore, Maryland. As noted above, Baltimore currently has rates of teen pregnancy that are significantly higher than statewide rates.5, 6 The United States Census estimates that there are 47,710 adolescents between the ages of 15-19 years in Baltimore. 7 Using 2007 Youth Risk Behavior Survey estimates, approximately 35,829 youth in this age group are having sexual intercourse and 13,302 are not using condoms for either STI or pregnancy prevention. 20 The current rise in birth rates to teens in urban Baltimore has prompted a joint initiative involving the mayor's office, Baltimore City Health Department, Urban Health Institute, and Healthy Teen Network.21
The Harriet Lane Clinic located in East Baltimore primarily serves low-income African American families from the neighboring communities. Adolescents and young adults in East Baltimore have high rates of pregnancy and STIs. During the 1st 12-months of funding of the Johns Hopkins Harriet Lane Teen Clinic's Title X Program, the majority of clients were females aged 15 to 25 years (83%), uninsured (52%), and minors seeking confidential services (50%). The program provides sexual/reproductive health services to young persons who are uninsured, underinsured and seeking confidential services. More than 80% of patients served by the clinic participate in a Medicaid Managed Care Organization. While there are approximately 250 individuals on the Depo-Provera logs, the Harriet Lane Clinic currently has more than 100 active users, but adherence to scheduled Depo-Provera appointments remains a problem despite access to care through our clinical site.
Recruitment:
Adolescent girls 13-21 who have 1) elected Depo-Provera for long-acting contraception and 2) have an active cell phone for their personal use will be asked by the adolescent nurse case manager and/or research staff at 1) routine clinical visits and 2) through telephone outreach if they would be willing to participate in a quality improvement intervention that involved random assignment to the text messaging intervention that reminds them of their next Depo-Provera visit via text message or the standard clinic reminders via phone.
All recruitment will take place in the confines of their private room during their routine clinical visits for family planning or via phone at the preferred contact number listed by the patient. The same degree of privacy will be afforded as during the clinical visit or during routine follow-up phone calls.
Randomization \& Blinding As noted in the above schematic, adolescents who agree to participate will be randomized to the intervention or control arms at the time of enrollment. A computer-generated randomization sequence for block randomization (5 units) will be employed. Ordered envelopes will be generated for each enrollment packet to guide the research staff regarding group assignment.
Interventions All adolescents will receive care from the Harriet Lane Adolescent Medicine Clinic according to the existing clinical protocol. During "Depo visits" patients receive a nursing assessment, medical assessment if indicated, counseling, and if all is well their next injection, an appointment card with the date of the next injection. Patients are also offered automatic clinic reminders via their home phone. All adolescents in the study will complete a baseline interview and brief follow-up interview at each visit based on the standard interviews conducted by staff at each Depo-Provera visit. Adolescents who are enrolled by phone will be asked the questions via phone and then interviewed at the next visit.
In addition to standard of care and brief study interviews, adolescents in the Depo-TEXT intervention will be provided with online enrollment in the Compliance for Life® (CFL) system through iReminder) to receive a welcome Message 24 hrs after enrollment, appointment reminders prior to 3 month injection cycles, monthly health reminders (condom use, weight control on Depo-Provera, side effect management, 6-month STD testing reminder, call for text replies to reschedule missed appointments.) Intervention participants will receive standard of care for those enrolled in the Depo-Provera clinical program through which a nurse case manager responds to self-activated queries for assistance and missed clinic appointments.
Patients will be followed for adherence for 2-3 Depo-Provera injection cycles depending on the time of enrollment.
Human subjects Protections:
All participants will provide informed oral consent and/or via phone and will be informed that their participation in the study will have no effect on subsequent medical care. All patient data will be kept confidential and secure by using subject ID numbers, electronic collection of survey information and storage on secure servers with password protection for access. All research team members on this project have been educated in the protection of human research participants and the treatment of protected health information as evidenced by completion of their institutional compliance courses. Research assistants have completed the compliance courses as a part of their staff training. We are also using an established provider of global, secure and regulatory HIPAA compliant patient communication solutions to healthcare and biopharmaceutical research sectors to engage adolescents using SMS technology.
- Conditions
- Contraceptive Behavior
- Being tested
- Text Messaging Intervention
- Keywords
- Depoprovera, Contraception, Appointment adherence/attendance, Pregnancy Prevention
- Medical subject headings
- Contraception Behavior
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Text Messaging InterventionBehavioural
Also called Compliance for Life®
- Online enrollment in the Compliance for Life® (CFL) system through iReminder)
- Welcome Message 24 hrs after enrollment
- Appointment Reminder prior to 3 month injection cycles
- Monthly health reminders i. Condom use ii. Weight control iii. Side Effect Management 5.6-month STD testing reminder
6.Call for missed appointment or no reply to appointment reminder (or other text message)
| Study group | Role | What they receive |
|---|---|---|
| Control | No intervention | Adolescents in the Control Arm received standard of care. They continue to receive the DepoProvera injections through scheduled appointment, but would not receive a call from the nurse case manager regarding DepoProvera appointments until they have missed their scheduled DepoProvera appointment. |
| Text Messaging Intervention | Experimental | Adolescents in the intervention arm receive text message reminders for appointments and positive sexual health messages regarding use of DepoProvera in between scheduled appointments. They are encouraged to seek care for assistance with obtaining condoms and/or if they are having problems with the medication. Receives: Behavioral: Text Messaging Intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Appointment Adherence (Efficacy)
Participants who returned on-time for appointments
Measured: 9 months
Responsiveness to Appointment Messages
Overall responsiveness to delivery confirmation requests with A) Appointment messages and B) Informational Messages
Measured: 9 months
Secondary outcomes (1)
Proportion of Patients Satisfied With Messaging Service
% of patients indicating satisfaction with the messaging reminder/health information service
Measured: 9 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2012 (estimated)
- Study startJan 2011
- Primary completionMar 2012
- Study completion1 Sep 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Contraceptive BehaviorStudies of the same condition, open and under way.
- More trials run by Johns Hopkins UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Investigator
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- Johns Hopkins University
- Sponsor type
- University, hospital or other
- Collaborators
- The Thomas Wilson Sanitarium for Children of Baltimore City
- Responsible party
- Sponsor
- Investigators
- Maria Trent, MD, MPH, Principal investigator, Johns Hopkins School of Medicine
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01641380
- Sponsor's protocol ID
- NA_00043284
- Acronym
- DepoText
- Status last verified
- Jan 2019
- First submitted
- 10 Jul 2012
- Last updated
- 2 Mar 2021
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- No
- Individual data sharing
- Undecided: De-identified data may be made available to researchers for subsequent analyses. It will be available upon final completion of the study. Data can be obtained by submitting an initial query for review by the principal investigator.
Study at a glance
From the registry record, last updated by the sponsor on 2 Mar 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Meaningful Use of Technology to Improve Health Care Delivery for Urban Adolescents: Focus on Teen Pregnancy Prevention (DepoText Study)
- ClinicalTrials.gov ID
- NCT01641380
- Acronym / sponsor ID
- DepoText / NA_00043284
- Conditions
- Contraceptive Behavior
- Keywords
- Depoprovera, Contraception, Appointment adherence/attendance, Pregnancy Prevention
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- Johns Hopkins UniversityUniversity, hospital or other
- Collaborators
- The Thomas Wilson Sanitarium for Children of Baltimore City
- Study start
- Jan 2011 (actual)
- Primary completion
- Mar 2012 (actual)
- Study completion
- 1 Sep 2017 (actual)
- First posted
- 16 Jul 2012 (estimated)
- Results
- Posted 20 Dec 2018
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
While there have been major declines in teenage pregnancy around the country, Baltimore, Maryland has continued to experience increases over the last several years. Access and adherence to contraception has been found to be a major contributor to declines in teen pregnancy worldwide. The aim of this proof of concept pilot project is to determine preliminary efficacy of the DepoText Intervention. We will randomize urban adolescent girls who have elected Depo-Provera for ongoing contraception to receive either standard counseling and clinic appointment reminders or a text messaging (DepoTEXT) follow-up intervention. Participants in the DepoTEXT intervention will receive reminders for clinic visits and encouraging messages each month for STI prevention. The primary outcome is the preliminary efficacy for improving appointment adherence.
Detailed description
Aims:
The aim of this proof of concept pilot project is to determine the feasibility and acceptability of a text messaging reminder system for communicating with urban adolescents using Depo-Provera for long-acting contraception. We will randomize urban adolescent girls who have elected Depo-Provera for ongoing contraception to receive either standard counseling and clinic appointment reminders or a text messaging (DepoTEXT) follow-up intervention. Participants in the DepoTEXT intervention will receive reminders for clinic visits and encouraging messages each month for STI prevention. The primary outcome is the preliminary efficacy for improving appointment adherence. Secondary measures include patient responsiveness to text messages and acceptability/satisfaction with this approach.
Setting and Participants:
This research study will be conducted in the Johns Hopkins Harriet Lane Clinic located Baltimore, Maryland. As noted above, Baltimore currently has rates of teen pregnancy that are significantly higher than statewide rates.5, 6 The United States Census estimates that there are 47,710 adolescents between the ages of 15-19 years in Baltimore. 7 Using 2007 Youth Risk Behavior Survey estimates, approximately 35,829 youth in this age group are having sexual intercourse and 13,302 are not using condoms for either STI or pregnancy prevention. 20 The current rise in birth rates to teens in urban Baltimore has prompted a joint initiative involving the mayor's office, Baltimore City Health Department, Urban Health Institute, and Healthy Teen Network.21
The Harriet Lane Clinic located in East Baltimore primarily serves low-income African American families from the neighboring communities. Adolescents and young adults in East Baltimore have high rates of pregnancy and STIs. During the 1st 12-months of funding of the Johns Hopkins Harriet Lane Teen Clinic's Title X Program, the majority of clients were females aged 15 to 25 years (83%), uninsured (52%), and minors seeking confidential services (50%). The program provides sexual/reproductive health services to young persons who are uninsured, underinsured and seeking confidential services. More than 80% of patients served by the clinic participate in a Medicaid Managed Care Organization. While there are approximately 250 individuals on the Depo-Provera logs, the Harriet Lane Clinic currently has more than 100 active users, but adherence to scheduled Depo-Provera appointments remains a problem despite access to care through our clinical site.
Recruitment:
Adolescent girls 13-21 who have 1) elected Depo-Provera for long-acting contraception and 2) have an active cell phone for their personal use will be asked by the adolescent nurse case manager and/or research staff at 1) routine clinical visits and 2) through telephone outreach if they would be willing to participate in a quality improvement intervention that involved random assignment to the text messaging intervention that reminds them of their next Depo-Provera visit via text message or the standard clinic reminders via phone.
All recruitment will take place in the confines of their private room during their routine clinical visits for family planning or via phone at the preferred contact number listed by the patient. The same degree of privacy will be afforded as during the clinical visit or during routine follow-up phone calls.
Randomization \& Blinding As noted in the above schematic, adolescents who agree to participate will be randomized to the intervention or control arms at the time of enrollment. A computer-generated randomization sequence for block randomization (5 units) will be employed. Ordered envelopes will be generated for each enrollment packet to guide the research staff regarding group assignment.
Interventions All adolescents will receive care from the Harriet Lane Adolescent Medicine Clinic according to the existing clinical protocol. During "Depo visits" patients receive a nursing assessment, medical assessment if indicated, counseling, and if all is well their next injection, an appointment card with the date of the next injection. Patients are also offered automatic clinic reminders via their home phone. All adolescents in the study will complete a baseline interview and brief follow-up interview at each visit based on the standard interviews conducted by staff at each Depo-Provera visit. Adolescents who are enrolled by phone will be asked the questions via phone and then interviewed at the next visit.
In addition to standard of care and brief study interviews, adolescents in the Depo-TEXT intervention will be provided with online enrollment in the Compliance for Life® (CFL) system through iReminder) to receive a welcome Message 24 hrs after enrollment, appointment reminders prior to 3 month injection cycles, monthly health reminders (condom use, weight control on Depo-Provera, side effect management, 6-month STD testing reminder, call for text replies to reschedule missed appointments.) Intervention participants will receive standard of care for those enrolled in the Depo-Provera clinical program through which a nurse case manager responds to self-activated queries for assistance and missed clinic appointments.
Patients will be followed for adherence for 2-3 Depo-Provera injection cycles depending on the time of enrollment.
Human subjects Protections:
All participants will provide informed oral consent and/or via phone and will be informed that their participation in the study will have no effect on subsequent medical care. All patient data will be kept confidential and secure by using subject ID numbers, electronic collection of survey information and storage on secure servers with password protection for access. All research team members on this project have been educated in the protection of human research participants and the treatment of protected health information as evidenced by completion of their institutional compliance courses. Research assistants have completed the compliance courses as a part of their staff training. We are also using an established provider of global, secure and regulatory HIPAA compliant patient communication solutions to healthcare and biopharmaceutical research sectors to engage adolescents using SMS technology.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Control | No intervention | –Adolescents in the Control Arm received standard of care. They continue to receive the DepoProvera injections through scheduled appointment, but would not receive a call from the nurse case manager regarding DepoProvera appointments until they have missed their scheduled DepoProvera appointment. |
| Text Messaging Intervention | Experimental | Behavioral: Text Messaging InterventionAdolescents in the intervention arm receive text message reminders for appointments and positive sexual health messages regarding use of DepoProvera in between scheduled appointments. They are encouraged to seek care for assistance with obtaining condoms and/or if they are having problems with the medication. |
Who may qualify
- Ages
- 13 to 21 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult
Key inclusion criteria (3 listed)
- Selected Depo-Provera for ongoing contraception
- Have a cell phone with text messaging capacity for personal use, and
- Agree to be randomized
Key exclusion criteria (2 listed)
- Adolescent girls using other forms of contraception
- Adolescents who do not have a cell phone w/ text messaging capability for personal use
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Text Messaging InterventionAlso: Compliance for Life®1. Online enrollment in the Compliance for Life® (CFL) system through iReminder) 2. Welcome Message 24 hrs after enrollment 3. Appointment Reminder prior to 3 month injection cycles 4. Monthly health reminders i. Condom use ii. Weight control iii. Side Effect Management 5.6-month STD testing reminder 6.Call for missed appointment or no reply to appointment reminder (or other text message) | Behavioural | Text Messaging Intervention |
Primary outcome
Appointment Adherence (Efficacy)
Time frame: 9 months
Participants who returned on-time for appointments
Responsiveness to Appointment Messages
Time frame: 9 months
Overall responsiveness to delivery confirmation requests with A) Appointment messages and B) Informational Messages
1 secondary outcome
Proportion of Patients Satisfied With Messaging Service
Time frame: 9 months
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Mar 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Registration link on Johns Hopkins ICTR Trials RegistryLink provided by the sponsor.
- Individual participant dataSharing planned: Undecided. De-identified data may be made available to researchers for subsequent analyses. It will be available upon final completion of the study. Data can be obtained by submitting an initial query for review by the principal investigator.
Related trials for Contraceptive Behavior
Recruiting
Estimating the Impact of Sexuality Education and Mobile Health Services on Reproductive Health and Empowerment Among Adolescents in Sierra Leone for the Family Planning Impact Lab
Reproductive Health, Sexual Health
Not yet recruitingObservational study
FLOW: Influence of the Menstrual Cycle on Alcohol Use in Women
Alcohol Use, Alcohol Consumption
Not yet recruiting
Impact of Gender-Transformative Interventions on Contraceptive Use and Reproductive Autonomy in Somalia
Contraceptive Behavior, Social Norms
Recruiting
Impact of Self-Care Family Planning Services on Health and Development in South Sudan (Family Planning Impact Lab)
Contraceptive Behavior, Self Administration
Recruiting
"Vasectomy: Right for Me?" Decision Support Tool
Vasectomy, Contraception
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Maria Trent, MD, MPH principal investigator
Johns Hopkins School of Medicine
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Text Messaging Intervention in people with Contraceptive Behavior, run by Johns Hopkins University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Mar 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 20 Dec 2018). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Appointment Adherence (Efficacy) (time frame: 9 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Mar 2021.